Listed

Halozyme Therapeutics, Inc.

HALONasdaqCIK 1159036HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$481.0mRevenue, Q2 FY2026, three months to 2026-06-30$481.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$481.0mRevenue, Q2 FY2026, three months to 2026-06-30$481.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure+47.7% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin59.8%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $287.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Revenue: $481.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure−2.3 pts on a year earlier
  • Net margin47.8%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $229.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Revenue: $481.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure−2.9 pts on a year earlier
  • Diluted EPS$1.90Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure+42.9% on a year earlier
  • Free cash flow$236.7mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $240.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001159036-26-000104. Derived: 6-month figure less the 3-month figure.Capital expenditure: $4.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001159036-26-000104. Derived: 6-month figure less the 3-month figure.Report this figure+141.2% on a year earlier

Last eight quarters

Full statements
Revenue$481.0mOperating margin 59.8%
Diluted EPS$1.90, Q2 FY2026
Free cash flow$236.7m, Q2 FY2026
Halozyme Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m290Revenue, Q3 FY2024, three months to 2024-09-30$290.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Report this figure298Revenue, Q4 FY2024, three months to 2024-12-31$298.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure265Revenue, Q1 FY2025, three months to 2025-03-31$264.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure326Revenue, Q2 FY2025, three months to 2025-06-30$325.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure354Revenue, Q3 FY2025, three months to 2025-09-30$354.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Report this figure452Revenue, Q4 FY2025, three months to 2025-12-31$451.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure377Revenue, Q1 FY2026, three months to 2026-03-31$376.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure481Revenue, Q2 FY2026, three months to 2026-06-30$481.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%56.3%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $163.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Revenue: $290.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Report this figure58.9%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $175.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Revenue: $298.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure53.4%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $141.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Revenue: $264.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure62.2%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $202.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Revenue: $325.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure61.5%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $217.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Revenue: $354.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Report this figure(20.6%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$92.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Revenue: $451.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure49.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $184.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Revenue: $376.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure59.8%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $287.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Revenue: $481.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure
Net margin%47.2%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $137.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Revenue: $290.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Report this figure46.0%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $137.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Revenue: $298.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure44.6%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $118.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Revenue: $264.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure50.7%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $165.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Revenue: $325.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure49.5%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $175.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Revenue: $354.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Report this figure(31.3%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$141.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Revenue: $451.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure39.8%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $150.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Revenue: $376.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure47.8%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $229.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Revenue: $481.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure
Diluted EPS$ per share1.05Diluted EPS, Q3 FY2024, three months to 2024-09-30$1.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Report this figurenot reported (Diluted EPS not reported)0.93Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure1.33Diluted EPS, Q2 FY2025, three months to 2025-06-30$1.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure1.43Diluted EPS, Q3 FY2025, three months to 2025-09-30$1.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001159036-25-000045.Report this figurenot reported (Diluted EPS not reported)1.22Diluted EPS, Q1 FY2026, three months to 2026-03-31$1.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure1.90Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001159036-26-000104.Report this figure
Free cash flow$m114Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $115.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001159036-25-000045. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0001159036-25-000045. Derived: 9-month figure less the 6-month figure.Report this figure175Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $178.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Capital expenditure: $3.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure153Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $154.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Capital expenditure: $950.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure98.1Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $99.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001159036-26-000104. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001159036-26-000104. Derived: 6-month figure less the 3-month figure.Report this figure176Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $178.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001159036-25-000045. Derived: 9-month figure less the 6-month figure.Capital expenditure: $3.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-03, accession 0001159036-25-000045. Derived: 9-month figure less the 6-month figure.Report this figure218Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $219.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001159036-26-000024. Derived: 12-month figure less the 9-month figure.Report this figure176Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $180.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Capital expenditure: $3.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001159036-26-000068.Report this figure237Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $240.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001159036-26-000104. Derived: 6-month figure less the 3-month figure.Capital expenditure: $4.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001159036-26-000104. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.40bnOperating margin 33.6%
Diluted EPS$2.56, FY2025
Free cash flow$644.6m, FY2025
Halozyme Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m443Revenue, FY2021, twelve months to 2021-12-31$443.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0001159036-24-000008.Report this figure660Revenue, FY2022, twelve months to 2022-12-31$660.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0001159036-25-000010.Report this figure829Revenue, FY2023, twelve months to 2023-12-31$829.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure1,015Revenue, FY2024, twelve months to 2024-12-31$1.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure1,397Revenue, FY2025, twelve months to 2025-12-31$1.40bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%62.2%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $275.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-20, accession 0001159036-24-000008.Revenue: $443.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0001159036-24-000008.Report this figure40.5%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $267.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-18, accession 0001159036-25-000010.Revenue: $660.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0001159036-25-000010.Report this figure40.7%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $337.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024.Revenue: $829.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure54.3%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $551.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024.Revenue: $1.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure33.6%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $469.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024.Revenue: $1.40bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure
Net margin%90.8%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $402.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-20, accession 0001159036-24-000008.Revenue: $443.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-20, accession 0001159036-24-000008.Report this figure30.6%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $202.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-18, accession 0001159036-25-000010.Revenue: $660.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-18, accession 0001159036-25-000010.Report this figure34.0%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $281.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024.Revenue: $829.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure43.7%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $444.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024.Revenue: $1.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure22.7%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $316.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-17, accession 0001159036-26-000024.Revenue: $1.40bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure
Diluted EPS$ per share2.74Diluted EPS, FY2021, twelve months to 2021-12-31$2.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-20, accession 0001159036-24-000008.Report this figure1.44Diluted EPS, FY2022, twelve months to 2022-12-31$1.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-18, accession 0001159036-25-000010.Report this figure2.10Diluted EPS, FY2023, twelve months to 2023-12-31$2.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure3.43Diluted EPS, FY2024, twelve months to 2024-12-31$3.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure2.56Diluted EPS, FY2025, twelve months to 2025-12-31$2.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure
Free cash flow$m298Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $299.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-20, accession 0001159036-24-000008.Capital expenditure: $1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-20, accession 0001159036-24-000008.Report this figure235Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $240.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-18, accession 0001159036-25-000010.Capital expenditure: $4.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-18, accession 0001159036-25-000010.Report this figure373Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $388.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001159036-26-000024.Capital expenditure: $15.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure468Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $479.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001159036-26-000024.Capital expenditure: $10.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure645Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $651.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-17, accession 0001159036-26-000024.Capital expenditure: $7.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-17, accession 0001159036-26-000024.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Halozyme Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$1.04bn13,271,095Added+6,042
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$418.8m5,351,312Added+80,094
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$414.8m5,299,008Added+49,802
STATE STREET CORP2026-06-30$405.4m5,179,434Added+241,580
Invesco Ltd.2026-06-30$248.7m3,177,997Reduced−834,497
MORGAN STANLEY2026-06-30$221.7m2,832,594Added+270,285
Boston Partners2026-06-30$216.8m2,773,568Added+89,885
BANK OF AMERICA CORP /DE/2026-06-30$214.5m2,740,561Reduced−172,548
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$197.3m2,519,951Added+14,165
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC2026-06-30$196.5m2,511,050Reduced−14,925

Recent filings

All 1,111 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Halozyme Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-09-3020:20 ET8-K5.02 Departure or appointment of officers or directors0001159036-26-000128
2026-09-2220:41 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0001193125-26-398015
2026-09-1812:23 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001159036-26-000126
2026-09-1620:32 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001159036-26-000121
2026-08-1820:04 ET8-K5.02 Departure or appointment of officers or directors0001159036-26-000106
2026-08-0620:11 ET10-QQuarterly reportPeriod 2026-06-300001159036-26-000104
2026-08-0620:08 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001159036-26-000103
2026-07-0220:10 ET8-K5.02 Departure or appointment of officers or directors0001159036-26-000088
2026-05-1120:09 ET10-QQuarterly reportPeriod 2026-03-310001159036-26-000068
2026-05-1120:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001159036-26-000067

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 17, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1159036
Tickers
HALO
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
HALOZYME THERAPEUTICS INC (to 2019-07-03); GLOBAL YACHT SERVICES INC (to 2004-03-12)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.